Sipuleucel-T

by admin_63069 | Jun 6, 2022 | Related Topics

An innovative immunotherapy option for metastatic castration-resistant prostate cancer

What’s New

Key Prostate Cancer Research
Cohort Study Identified Optimal Minimum Treatment Duration for ADT in High-Risk Prostate Cancer
MRI-Guided HIFU Effective in Intermediate-Risk Prostate Cancer
The Future of Metastatic Prostate Cancer Management
Researchers Uncover Mechanism By Which Prostate Cancer Becomes Resistant

Disclaimers:

PCSANM provides education, information, and support, not medical advice. Please contact your physician for all your medical concerns. No copyrighted material belonging to others is knowingly used without permission. If any is inadvertently used without permission, please contact our office. Articles are selected from a variety of sources to give as wide a range of content as possible. PCSANM does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.

2533 Virginia St. NE, Suite C Albuquerque, NM 87110

Phone: (505) 254-7784
Toll Free: (800) 278-7678
Fax: (505) 254-7786

Email: pchelp@pcsanm.org